Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Status:
Completed
Trial end date:
2021-07-09
Target enrollment:
Participant gender:
Summary
Hematopoietic stem cell transplantation is a procedure in which a person receives blood
forming stem cells from a person called a "donor." The stem cells can be obtained from the
hollow part of the hip bone or from blood.
A serious problem with this treatment is graft-versus-host disease (GVHD). This happens when
stem cells from the donor attack normal cells of the recipient. Currently, there is no
universal standard of care in the United States to prevent GVHD.
This study is being done to see if a medicine that is used to lower cholesterol can also help
in reducing GVHD.
Patients will receive atorvastatin daily by mouth starting 14 days before stem cell
transplant. They will continue to take atorvastatin until 180 days after transplant. This
medicine may be stopped earlier if there is a bad side effect or a severe GVHD. Patients will
also receive standard treatment to prevent GVHD. Patients will undergo many tests that are
standard for their treatment at West Virginia University (WVU), including blood tests to
check blood counts, kidney function and HIV status; blood test to check for pregnancy; Multi
Gated Acquisition Scan (MUGA scan)or echocardiogram to test heart function; lung function
testing; and bone marrow aspirate or biopsy. Patients will also have the option to provide
blood samples for optional research related to the study.